Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression
2017 | journal article
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression
Bartels, C. ; Wagner, M.; Wolfsgruber, S.; Ehrenreich, H. & Schneider, A. (2017)
American Journal of Psychiatry,. DOI: https://doi.org/10.1176/appi.ajp.2017.17040404
Documents & Media
Details
- Authors
- Bartels, Claudia ; Wagner, Michael; Wolfsgruber, Steffen; Ehrenreich, Hannelore ; Schneider, Anja
- Abstract
- Objective: Depression is associated with an increased risk of Alzheimer’s disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer’s dementia. Method: Data sets from 755 currently nondepressed participants from the longitudinal Alzheimer’s Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates. Results: In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer’s dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. Conclusions: Long-term SSRI treatment may delay progression from MCI to Alzheimer’s dementia.
- Issue Date
- 2017
- Journal
- American Journal of Psychiatry
- ISSN
- 0002-953X; 1535-7228
- Language
- English